22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › SAREPTA THERAPEUTICS INC. › 2024-2025

SAREPTA THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and SAREPTA THERAPEUTICS INC.’s Form 8-K, filed June 6, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 8Ballot items
  • 478Asset managers, any item
  • 3,760Fund votes
  • June 5, 2025Meeting date

Results at a glance

Meeting of June 5, 2025: 8 items on SAREPTA THERAPEUTICS INC.’s Form 8-K, filed June 6, 2025: 4 elected · 4 approved.

Dissent

Notable dissent: 1 director (12.9% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore SAREPTA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by SAREPTA THERAPEUTICS INC.

These tallies are SAREPTA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SAREPTA THERAPEUTICS INC. — official shareholder meeting results, meeting held June 5, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Richard J. Barry 64,757,6859,565,54760,768 --10,202,114 87%Elected—
Elect Director: M. Kathleen Behrens, Ph.D. 69,004,0245,336,94343,033 --10,202,114 93%Elected—
Elect Director: Stephen L. Mayo, Ph.D. 73,289,6531,051,65642,691 --10,202,114 99%Elected—
Elect Director: Claude Nicaise, M.D. 71,006,4753,334,91442,611 --10,202,114 96%Elected—
2. Advisory Vote to Approve Named Executive Officer Compensation 72,144,2922,176,99862,710 --10,202,114 97%Approved—
3. Amendment to the Company's 2018 Equity Incentive Plan 71,084,9473,248,69950,354 --10,202,114 96%Approved—
4. Amendment to the Company's Amended and Restated 2013 Employee Stock Purchase Plan 73,725,724629,17029,106 --10,202,114 99.2%Approved—
5. Ratification of KPMG as the Company's Independent Registered Public Accounting Firm 80,588,1153,875,497122,502 ---- 95%Approved—

Source: SAREPTA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 6, 2025 — read the filing on EDGAR.

How asset managers voted at the SAREPTA THERAPEUTICS INC. 2024-2025 meeting

478 asset managers disclosed a vote on at least one SAREPTA THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Claude Nicaise, M.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 71,006,475AGAINST: 3,334,914
Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: CLAUDE NICAISE, M.D.

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Claude Nicaise, M.D.”): 71,006,475 for, 3,334,914 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class II for a term of two years.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 109 asset managers voting on “TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR S” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,173,5940 00For
Capital Group5,853,5840 00For
BlackRock5,747,4700 00For
AMCAP FUND2,658,3670 00For
Fidelity2,260,0220 00For
State Street1,867,3710 00For
JANUS INVESTMENT FUND1,364,2410 00For
T. Rowe Price823,977119,182 00Mixed
Charles Schwab646,6490 00For
Aberdeen618,3140 00For
Federated Hermes446,3880 00For
JPMorgan312,1450 00For
Columbia Threadneedle311,3650 00For
Jackson National302,7100 00For
First Trust301,0140 00For
Dimensional276,6100 00For
CARILLON SERIES TRUST249,7150 00For
TIAA244,4270 00For
John Hancock244,2870 00For
MUTUAL FUND SERIES TRUST214,2180 00For
Equitable101,734105,439 00Mixed
AIG/SunAmerica150,2650 00For
Advantage Advisers Xanthus Fund, L.L.C.122,5160 00For
Empower109,1730 00For
Voya96,0320 00For

Fund voting reports, all 109 managers: 38,186,273 for, 302,007 against, 18,186 abstained, 39 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR S” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH976,0000 00For

Institutional-manager reports, all 1 managers: 976,000 for.

Elect Director: M. Kathleen Behrens, Ph.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 69,004,024AGAINST: 5,336,943
Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: M. KATHLEEN BEHRENS, PH.D.

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: M. Kathleen Behrens, Ph.D.”): 69,004,024 for, 5,336,943 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class II for a term of two years.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 109 asset managers voting on “TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR S” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,172,4721,122 00For
Capital Group5,853,5840 00For
BlackRock5,747,4700 00For
AMCAP FUND2,658,3670 00For
Fidelity2,260,0220 00For
State Street1,867,28289 00For
JANUS INVESTMENT FUND1,364,2410 00For
T. Rowe Price0943,159 00Against
Charles Schwab646,6490 00For
Aberdeen618,3140 00For
Federated Hermes446,3880 00For
JPMorgan312,1450 00For
Columbia Threadneedle311,3650 00For
Jackson National191,766110,944 00Mixed
First Trust301,0140 00For
Dimensional276,6100 00For
CARILLON SERIES TRUST249,7150 00For
TIAA244,4270 00For
John Hancock244,2870 00For
MUTUAL FUND SERIES TRUST214,2180 00For
Equitable101,734105,439 00Mixed
AIG/SunAmerica150,2650 00For
Advantage Advisers Xanthus Fund, L.L.C.122,5160 00For
Empower57,40551,768 00Mixed
Voya96,0320 00For

Fund voting reports, all 109 managers: 36,996,696 for, 1,491,584 against, 18,186 abstained, 39 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR S” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH976,0000 00For

Institutional-manager reports, all 1 managers: 976,000 for.

Elect Director: Richard J. Barry

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 64,757,685AGAINST: 9,565,547
Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: RICHARD J. BARRY

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Richard J. Barry”): 64,757,685 for, 9,565,547 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class II for a term of two years.”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 109 asset managers voting on “TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR S” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,172,4711,123 00For
Capital Group5,853,5840 00For
BlackRock5,747,4700 00For
AMCAP FUND2,658,3670 00For
Fidelity2,260,0220 00For
State Street6,0741,861,297 00Against
JANUS INVESTMENT FUND1,364,2410 00For
T. Rowe Price0943,159 00Against
Charles Schwab646,6490 00For
Aberdeen618,3140 00For
Federated Hermes446,3880 00For
JPMorgan312,1450 00For
Columbia Threadneedle311,3650 00For
Jackson National191,766110,944 00Mixed
First Trust301,0140 00For
Dimensional276,6100 00For
CARILLON SERIES TRUST249,7150 00For
TIAA244,4270 00For
John Hancock244,2870 00For
MUTUAL FUND SERIES TRUST214,2180 00For
Equitable101,734105,439 00Mixed
AIG/SunAmerica150,2650 00For
Advantage Advisers Xanthus Fund, L.L.C.122,5160 00For
Empower57,40551,768 00Mixed
Voya96,0320 00For

Fund voting reports, all 109 managers: 34,850,505 for, 3,637,775 against, 18,186 abstained, 39 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR S” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH976,0000 00For

Institutional-manager reports, all 1 managers: 976,000 for.

Elect Director: Stephen L. Mayo, Ph.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 73,289,653AGAINST: 1,051,656
Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: STEPHEN L. MAYO, PH.D.

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Stephen L. Mayo, Ph.D.”): 73,289,653 for, 1,051,656 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class II for a term of two years.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 109 asset managers voting on “TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR S” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,173,5940 00For
Capital Group5,853,5840 00For
BlackRock5,747,4700 00For
AMCAP FUND2,658,3670 00For
Fidelity2,260,0220 00For
State Street1,867,3710 00For
JANUS INVESTMENT FUND1,364,2410 00For
T. Rowe Price823,977119,182 00Mixed
Charles Schwab646,6490 00For
Aberdeen618,3140 00For
Federated Hermes446,3880 00For
JPMorgan312,1450 00For
Columbia Threadneedle311,3650 00For
Jackson National302,7100 00For
First Trust301,0140 00For
Dimensional276,6100 00For
CARILLON SERIES TRUST249,7150 00For
TIAA244,4270 00For
John Hancock244,2870 00For
MUTUAL FUND SERIES TRUST214,2180 00For
Equitable101,734105,439 00Mixed
AIG/SunAmerica150,2650 00For
Advantage Advisers Xanthus Fund, L.L.C.122,5160 00For
Empower109,1730 00For
Voya96,0320 00For

Fund voting reports, all 109 managers: 38,197,273 for, 291,007 against, 18,186 abstained, 39 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR S” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH976,0000 00For

Institutional-manager reports, all 1 managers: 976,000 for.

Amendment to the Company's Amended and Restated 2013 Employee Stock Purchase Plan

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

99.2% Approved · of votes cast

FOR 99.2%
FOR: 73,725,724AGAINST: 629,170
Details: description as filed, official tally, votes by 114 asset managers

Description as filed by funds: APPROVE AN AMENDMENT TO THE AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN (AS AMENDED AND RESTATED ON JUNE 27, 2016, AND AMENDED ON JUNE 6, 2019 AND ON JUNE 8, 2023) (THE "2016 ESPP") TO INCREASE THE NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE 2016 ESPP BY 300,000 SHARES TO 1,700,000 SHARES

SAREPTA THERAPEUTICS INC.’s own tally for this item (“4. Amendment to the Company's Amended and Restated 2013 Employee Stock Purchase Plan”): 73,725,724 for, 629,170 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4: Amendment to the Company's Amended and Restated 2013 Employee Stock Purchase Plan The stockholders approved the 2016 ESPP Amendment.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of SAREPTA THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “Amend Stock Compensation Plan” (2 managers, 4,033 for, 3 against).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 111 asset managers voting on “APPROVE AN AMENDMENT TO THE AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN (AS AMENDED AND RESTATED ON” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,173,5940 00For
Capital Group5,853,5840 00For
BlackRock5,747,4700 00For
AMCAP FUND2,658,3670 00For
Fidelity2,260,0220 00For
State Street1,867,3710 00For
JANUS INVESTMENT FUND1,364,2410 00For
T. Rowe Price943,1590 00For
Charles Schwab646,6490 00For
Aberdeen618,3140 00For
Federated Hermes446,3880 00For
JPMorgan312,1450 00For
Columbia Threadneedle311,3650 00For
Jackson National302,7100 00For
First Trust301,0140 00For
Dimensional276,6100 00For
CARILLON SERIES TRUST249,7150 00For
TIAA244,4270 00For
John Hancock244,2870 00For
MUTUAL FUND SERIES TRUST214,2180 00For
Equitable207,1730 00For
AIG/SunAmerica150,2650 00For
Advantage Advisers Xanthus Fund, L.L.C.122,5160 00For
Empower109,1730 00For
Voya96,0320 00For

Fund voting reports, all 111 managers: 38,492,431 for, 18,186 against, 0 abstained, 39 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “APPROVE AN AMENDMENT TO THE AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN (AS AMENDED AND RESTATED ON” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH976,0000 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC1,0890 00For
VOISARD ASSET MANAGEMENT GROUP, INC.30 00For

Institutional-manager reports, all 3 managers: 977,092 for.

Amendment to the Company's 2018 Equity Incentive Plan

Official resultCOMPENSATIONReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 71,084,947AGAINST: 3,248,699
Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: APPROVE AN AMENDMENT TO THE COMPANY'S 2018 EQUITY INCENTIVE PLAN (THE "2018 PLAN") TO INCREASE THE MAXIMUM AGGREGATE NUMBER OF SHARES OF COMMON STOCK THAT MAY BE ISSUED PURSUANT TO AWARDS GRANTED UNDER THE 2018 PLAN BY 4,300,000 SHARES TO 17,487,596 SHARES

SAREPTA THERAPEUTICS INC.’s own tally for this item (“3. Amendment to the Company's 2018 Equity Incentive Plan”): 71,084,947 for, 3,248,699 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Amendment to the Company's 2018 Equity Incentive Plan The stockholders approved the 2018 Plan Amendment.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 110 asset managers below reported 38,218,210 for, 236,388 against, 18,186 abstained, 39 not voted.

FOR
FOR: 38,218,210AGAINST: 236,388ABSTAIN: 18,186NOT VOTED: 39
Largest asset managers voting on “APPROVE AN AMENDMENT TO THE COMPANY'S 2018 EQUITY INCENTIVE PLAN (THE "2018 PLAN") TO INCREASE THE MAXIMUM AGG” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,173,5940 00For
Capital Group5,853,5840 00For
BlackRock5,747,4700 00For
AMCAP FUND2,658,3670 00For
Fidelity2,075,086184,936 00Mixed
State Street1,867,32942 00For
JANUS INVESTMENT FUND1,364,2410 00For
T. Rowe Price943,1590 00For
Charles Schwab646,6490 00For
Aberdeen618,3140 00For
Federated Hermes446,3880 00For
JPMorgan312,1450 00For
Columbia Threadneedle311,3650 00For
Jackson National302,7100 00For
First Trust301,0140 00For
Dimensional276,6100 00For
CARILLON SERIES TRUST249,7150 00For
TIAA244,4270 00For
John Hancock244,2870 00For
MUTUAL FUND SERIES TRUST214,2180 00For
Equitable207,1730 00For
AIG/SunAmerica150,2650 00For
Advantage Advisers Xanthus Fund, L.L.C.122,5160 00For
Voya96,0320 00For
Allspring84,6120 00For

Showing the 25 largest of 110 asset managers. All 110 are in the interactive database (link above).

Advisory Vote to Approve Named Executive Officer Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 14 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 72,144,292AGAINST: 2,176,998

Prior year: 87.6% for (June 6, 2024 meeting) ▲ 9.5 pts

Details: description as filed, official tally, votes by 475 asset managers

Description as filed by funds: ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION

SAREPTA THERAPEUTICS INC.’s own tally for this item (“2. Advisory Vote to Approve Named Executive Officer Compensation”): 72,144,292 for, 2,176,998 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for 2024.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 111 asset managers voting on “ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,173,5940 00For
Capital Group5,853,5840 00For
BlackRock5,747,4700 00For
AMCAP FUND2,658,3670 00For
Fidelity2,260,0220 00For
State Street1,867,3710 00For
JANUS INVESTMENT FUND1,364,2410 00For
T. Rowe Price943,1590 00For
Charles Schwab646,6490 00For
Aberdeen618,3140 00For
Federated Hermes446,3880 00For
JPMorgan312,1450 00For
Columbia Threadneedle311,3650 00For
Jackson National302,7100 00For
First Trust301,0140 00For
Dimensional276,6100 00For
CARILLON SERIES TRUST249,7150 00For
TIAA244,4270 00For
John Hancock244,2870 00For
MUTUAL FUND SERIES TRUST214,2180 00For
Equitable207,1730 00For
AIG/SunAmerica150,2650 00For
Advantage Advisers Xanthus Fund, L.L.C.122,5160 00For
Empower109,1730 00For
Voya96,0320 00For

Fund voting reports, all 111 managers: 38,464,340 for, 28,091 against, 18,186 abstained, 39 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 390 asset managers voting on “ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group9,009,9110 00For
State Street3,843,5820 00For
BlackRock3,258,704548 00For
Wellington2,881,6770 00For
EcoR1 Capital, LLC2,800,0000 00For
Janus Henderson2,465,7320 00For
Avoro Capital Advisors LLC2,322,4890 00For
JPMorgan2,010,3290 00For
T. Rowe Price1,880,2660 00For
GEODE CAPITAL MANAGEMENT, LLC1,816,6590 00For
Camber Capital Management LP1,000,0000 00For
Erste Asset Management GmbH976,0000 00For
Deep Track Capital, LP899,7310 00For
PICTET ASSET MANAGEMENT SA700,6170 00For
MELLON INVESTMENTS Corp667,0420 00For
Charles Schwab658,1180 00For
Aberdeen650,2790 00For
Northern Trust643,6940 00For
Federated Hermes514,4710 00For
John Hancock367,1380 00For
ALKEON CAPITAL MANAGEMENT LLC332,3610 00For
EAGLE ASSET MANAGEMENT INC324,6950 00For
Fiera Capital Corp300,5470 00For
Amundi0285,874 00Against
Brandywine Global Investment Management, LLC0261,547 00Against

Institutional-manager reports, all 390 managers: 47,138,357 for, 1,476,418 against, 2,969 abstained, 1,622 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of KPMG as the Company's Independent Registered Public Accounting Firm

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 80,588,115AGAINST: 3,875,497

Prior year: 95.3% for (June 6, 2024 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 113 asset managers

Description as filed by funds: RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE CURRENT YEAR ENDING DECEMBER 31, 2025

SAREPTA THERAPEUTICS INC.’s own tally for this item (“5. Ratification of KPMG as the Company's Independent Registered Public Accounting Firm”): 80,588,115 for, 3,875,497 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 5: Ratification of KPMG as the Company's Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2025.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 111 asset managers voting on “RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE CURREN” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,172,4721,122 00For
Capital Group5,853,5840 00For
BlackRock5,747,4700 00For
AMCAP FUND2,658,3670 00For
Fidelity2,260,0220 00For
State Street1,866,769602 00For
JANUS INVESTMENT FUND1,364,2410 00For
T. Rowe Price943,1590 00For
Charles Schwab646,6490 00For
Aberdeen618,3140 00For
Federated Hermes446,3880 00For
JPMorgan312,1450 00For
Columbia Threadneedle311,3650 00For
Jackson National302,7100 00For
First Trust301,0140 00For
Dimensional276,6100 00For
CARILLON SERIES TRUST249,7150 00For
TIAA244,4270 00For
John Hancock244,2870 00For
MUTUAL FUND SERIES TRUST214,2180 00For
Equitable207,1730 00For
AIG/SunAmerica150,2650 00For
Advantage Advisers Xanthus Fund, L.L.C.122,5160 00For
Empower109,1730 00For
Voya96,0320 00For

Fund voting reports, all 111 managers: 38,397,618 for, 94,818 against, 18,186 abstained, 39 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 2 asset managers voting on “RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE CURREN” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH976,0000 00For
VOISARD ASSET MANAGEMENT GROUP, INC.30 00For

Institutional-manager reports, all 2 managers: 976,003 for.

Largest SAREPTA THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 98,254,898 shares outstanding at the time of that meeting.

Fund voting reports: top SAREPTA THERAPEUTICS INC. shareholders by shares voted on “ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 11.37%
2Capital Group 5.96%
3BlackRock 5.85%
4AMCAP FUND 2.71%
5Fidelity 2.30%
6State Street 1.90%
7JANUS INVESTMENT FUND 1.39%
8T. Rowe Price 0.96%
9Charles Schwab 0.66%
10Aberdeen 0.63%
Institutional-manager reports: top SAREPTA THERAPEUTICS INC. shareholders by shares voted on “ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION”, 2024-2025
#Asset manager % of shares outstanding
1Capital Group 9.17%
2State Street 3.91%
3BlackRock 3.32%
4Wellington 2.93%
5EcoR1 Capital, LLC 2.85%
6Janus Henderson 2.51%
7Avoro Capital Advisors LLC 2.36%
8JPMorgan 2.05%
9T. Rowe Price 1.91%
10GEODE CAPITAL MANAGEMENT, LLC 1.85%

Reported SAREPTA THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

SAREPTA THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Shares Issued and Outstanding 4/8/202598,256,898 —Proxy statement (DEF 14A), proxy filed April 24, 2025
BlackRock9,906,868 —Form 13F, quarter ended March 31, 2025
Capital International Investors8,896,223 —Proxy statement (DEF 14A), proxy filed April 24, 2025
The Vanguard Group8,816,124 —Proxy statement (DEF 14A), proxy filed April 24, 2025
AQR Capital Management, LLC8,104,869 —Schedule 13G, filed February 13, 2026
Vanguard Portfolio Management6,751,168 —Schedule 13G, filed April 29, 2026
State Street4,068,472 —Form 13F, quarter ended March 31, 2025
Richard J. Barry3,233,787 —Proxy statement (DEF 14A), proxy filed April 24, 2025
Wellington Management2,646,619 —Form 13F, quarter ended March 31, 2025
Douglas S. Ingram2,590,417 —Proxy statement (DEF 14A), proxy filed April 24, 2025

Percentages above are of 98,254,898 shares outstanding, as reported by SAREPTA THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At SAREPTA THERAPEUTICS INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 478 asset managers reported votes on at least one of its 8 ballot items in their SEC Form N-PX filings, covering 3,760 separate fund positions. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION — SAREPTA THERAPEUTICS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: SAREPTA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SAREPTA THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

SAREPTA THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “SAREPTA THERAPEUTICS (SRPT) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/sarepta-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.